Carbohydrate Metabolism Practice Questions

Q: A patient presents with muscle cramps on exercise and positive myoglobinemia. What is the most likely disorder?

McArdle's disease. **Explanation:** The clinical presentation of **muscle cramps during exercise** followed by **myoglobinuria** (indicated by myoglobinemia) is the classic triad of **McArdle’s Disease (GSD Type V)**. **1. Why McArdle’s Disease is Correct:** McArdle’s disease is caused by a deficiency of **muscle glycogen phosphorylase** (myophosphorylase). This enzyme is essential for glycogenolysis—breaking down muscle glycogen into glucose-1-phosphate to provide energy during anaerobic exercise. Without it, muscles face an acute energy crisis during exertion, leading to painful cramps, rhabdomyolysis (muscle breakdown), and the release of myoglobin into the blood and urine. **2. Why Other Options are Incorrect:** * **Pompe’s Disease (GSD Type II):** Caused by **acid maltase** deficiency. It primarily presents as progressive muscle weakness and **cardiomegaly** (in infants). It does not typically cause exercise-induced cramps or acute myoglobinuria. * **Myotonia Congenita:** A chloride channelopathy characterized by **delayed muscle relaxation** (stiffness) after voluntary contraction (e.g., difficulty releasing a handshake), not exercise-induced breakdown. * **Myotonic Dystrophy:** A multisystem genetic disorder presenting with muscle wasting, cataracts, frontal balding, and arrhythmias. It involves "anticipation" due to CTG repeats, not acute metabolic crises during exercise. **3. High-Yield Clinical Pearls for NEET-PG:** * **"Second Wind" Phenomenon:** A hallmark of McArdle’s where symptoms improve after a few minutes of exercise as the body switches to using fatty acids and blood glucose. * **Ischemic Forearm Exercise Test:** Shows a **failure of blood lactate to rise** (since glycogen cannot be converted to lactate), while ammonia levels rise significantly. * **Biochemical Defect:** Deficiency of Myophosphorylase (encoded by the *PYGM* gene).

Q: Conversion of lactate to glucose requires all except?

Phosphofructokinase. ### Explanation The conversion of lactate to glucose occurs via **Gluconeogenesis**, primarily in the liver (Cori Cycle). Gluconeogenesis is not a simple reversal of glycolysis because three steps in glycolysis are irreversible. These "bottlenecks" must be bypassed by specific gluconeogenic enzymes. **Why Phosphofructokinase (PFK) is the correct answer:** PFK is a key regulatory enzyme of **Glycolysis**. It converts Fructose-6-Phosphate to Fructose-1,6-Bisphosphate. In gluconeogenesis, this step must be bypassed. The enzyme used for the reverse reaction is **Fructose-1,6-bisphosphatase**. Therefore, PFK is not required for synthesizing glucose; in fact, it is inhibited during gluconeogenesis to prevent a futile cycle. **Analysis of Incorrect Options:** * **Pyruvate Carboxylase (A):** Required to bypass Pyruvate Kinase. It converts pyruvate (derived from lactate) into oxaloacetate. It requires **Biotin** as a cofactor. * **PEP Carboxykinase (C):** Required to convert oxaloacetate into Phosphoenolpyruvate (PEP). * **Glucose-6-phosphatase (D):** The final bypass enzyme found in the endoplasmic reticulum of the liver and kidney. It converts Glucose-6-Phosphate to free Glucose, allowing it to enter the bloodstream. **High-Yield Clinical Pearls for NEET-PG:** * **The Cori Cycle:** Lactate produced by anaerobic glycolysis in muscles/RBCs travels to the liver to be converted back to glucose. * **Key Bypass Enzymes:** Remember the "Big 4" of Gluconeogenesis: Pyruvate Carboxylase, PEP Carboxykinase, Fructose-1,6-bisphosphatase, and Glucose-6-phosphatase. * **Energy Requirement:** Synthesis of 1 mole of glucose from 2 moles of lactate requires **6 ATP**. * **Deficiency:** Deficiency of Glucose-6-phosphatase leads to **Von Gierke’s Disease (GSD Type I)**, characterized by severe fasting hypoglycemia and lactic acidosis.

Q: A newborn baby presents with a history of seizures and hepatomegaly. The following feature was noted on ophthalmic examination. What is the most probable diagnosis?

Deficiency of Galactose 1-phosphate Uridyltransferase. ***Deficiency of Galactose 1-phosphate Uridyltransferase*** - This is **classic galactosemia (GALT deficiency)** presenting with the characteristic triad of **neonatal jaundice/hepatomegaly**, **E. coli sepsis**, and **oil-droplet nuclear cataracts**. - The combination of **seizures**, **hepatomegaly**, and **cataracts** in a newborn strongly indicates **galactose-1-phosphate uridyltransferase deficiency**. *Deficiency of Galactokinase* - Causes **isolated cataracts only** without systemic manifestations like hepatomegaly or seizures. - This is a **milder form** of galactosemia that does not present with the **multisystem involvement** seen in this case. *Deficiency of Ceruloplasmin* - This refers to **Wilson's disease**, which typically presents in **older children or adults** with hepatic and neurological symptoms. - **Kayser-Fleischer rings** in the cornea are characteristic, not the **oil-droplet cataracts** described in galactosemia. *Maternal exposure to X-rays in the antenatal period* - Would cause **congenital malformations** or **growth retardation** rather than the specific metabolic presentation described. - Does not explain the **characteristic cataracts** and **hepatomegaly** pattern seen in galactosemia.

Q: Which of the following types of reaction does NOT occur in glycolysis?

Hydration. **Explanation:** In glycolysis, glucose is converted into pyruvate through a series of ten enzymatic steps. To identify the correct answer, we must analyze the chemical transformations occurring in this pathway. **Why "Hydration" is the correct answer:** Hydration involves the **addition of water** across a double bond. In glycolysis, the reaction catalyzed by **Enolase** (Step 9) converts 2-phosphoglycerate to phosphoenolpyruvate (PEP). This is a **Dehydration** reaction (removal of water), not hydration. While hydration occurs in the TCA cycle (e.g., Fumarase reaction), it does not occur in glycolysis. **Analysis of Incorrect Options:** * **Isomerization:** Occurs multiple times. Examples include Glucose-6-P to Fructose-6-P (Phosphohexose isomerase) and Dihydroxyacetone phosphate to Glyceraldehyde-3-P (Triose phosphate isomerase). * **Phosphoryl transfer:** This is the hallmark of the "investment" and "payoff" phases. Kinases (Hexokinase, PFK-1, Phosphoglycerate kinase, and Pyruvate kinase) transfer phosphate groups between ATP/ADP and substrate molecules. * **Aldol cleavage:** Catalyzed by **Aldolase** (Step 4), which cleaves the 6-carbon Fructose-1,6-bisphosphate into two 3-carbon molecules (DHAP and Glyceraldehyde-3-P). **High-Yield Clinical Pearls for NEET-PG:** * **Rate-limiting step:** Phosphofructokinase-1 (PFK-1). * **Enolase Inhibition:** Fluoride inhibits Enolase by competing with Magnesium. This is why fluoride is added to blood collection tubes (grey top) to prevent glycolysis during glucose estimation. * **Arsenic Poisoning:** Arsenate competes with inorganic phosphate in the Glyceraldehyde-3-P dehydrogenase reaction, leading to ATP bypass (zero net ATP production). * **Rapoport-Luebering Cycle:** In RBCs, 1,3-BPG can be converted to 2,3-BPG, which shifts the oxygen dissociation curve to the right.

Q: For which glycogen storage disease, enzyme replacement therapy is available?

Glycogen storage disease type II. **Explanation:** **Glycogen Storage Disease Type II (Pompe Disease)** is the correct answer because it is the only GSD that is also classified as a **lysosomal storage disorder**. It is caused by a deficiency of **Acid α-1,4-glucosidase (Acid Maltase)**, the enzyme responsible for breaking down glycogen within lysosomes. Since the pathology involves a single lysosomal enzyme deficiency, it is amenable to **Enzyme Replacement Therapy (ERT)**. The FDA-approved recombinant human enzyme **Alglucosidase alfa** (and newer generations like Avalglucosidase alfa) is used to improve cardiac and skeletal muscle function in these patients. **Analysis of Incorrect Options:** * **GSD Type I (von Gierke Disease):** Caused by Glucose-6-Phosphatase deficiency. It is a metabolic pathway defect in the cytosol/ER of hepatocytes. Management focuses on dietary prevention of hypoglycemia (e.g., uncooked cornstarch). * **GSD Type III (Cori Disease):** Caused by Debranching enzyme deficiency. Management is primarily nutritional (high protein, frequent meals). * **GSD Type IV (Andersen Disease):** Caused by Branching enzyme deficiency, leading to the accumulation of abnormal glycogen (amylopectin-like). Treatment is supportive, often requiring liver transplantation. **High-Yield Clinical Pearls for NEET-PG:** * **Pompe is Unique:** It is the only GSD with **normal blood glucose levels** (no hypoglycemia) because cytosolic glycogenolysis remains intact. * **Clinical Triad:** Cardiomegaly (massive), hypotonia ("floppy baby"), and early death from heart failure. * **Histology:** PAS-positive material in lysosomes. * **Mnemonic:** "Pompe trashes the **Pump** (heart)."

Q: What is the first product of glycogenolysis?

Glucose-1-phosphate. ### Explanation **Correct Option: C. Glucose-1-phosphate** Glycogenolysis is the biochemical breakdown of glycogen into glucose. The process begins with the enzyme **Glycogen Phosphorylase**, which is the rate-limiting enzyme of this pathway. It acts on the $\alpha(1\to4)$ glycosidic bonds at the non-reducing ends of the glycogen chain. Instead of using water (hydrolysis), it uses inorganic phosphate ($P_i$) to cleave the bond—a process called **phosphorolysis**. This reaction releases **Glucose-1-phosphate (G1P)** as the primary initial product. **Analysis of Incorrect Options:** * **A. Glucose-6-phosphate:** While G1P is eventually converted to G6P by the enzyme *Phosphoglucomutase*, G6P is the *second* intermediate, not the first product. * **B. Glucose-1,6-diphosphate:** This is a transient intermediate/cofactor involved in the Phosphoglucomutase reaction, but it is not a primary product of glycogen breakdown. * **D. Fructose-1-phosphate:** This is an intermediate of **fructose metabolism** (fructolysis), produced by the action of Fructokinase in the liver. It has no role in glycogenolysis. **High-Yield Clinical Pearls for NEET-PG:** * **The 90:10 Rule:** Approximately 90% of glycogen breakdown yields **G1P** (via phosphorylase). The remaining 10% (at the $\alpha(1\to6)$ branch points) is released as **free glucose** by the Debranching enzyme ($\alpha$-1,6-glucosidase activity). * **Key Enzyme:** Glycogen Phosphorylase requires **Pyridoxal Phosphate (Vitamin B6)** as a mandatory cofactor. * **Tissue Specificity:** In the **liver**, G6P is converted to free glucose (via Glucose-6-phosphatase) to maintain blood sugar. In **muscle**, Glucose-6-phosphatase is absent; therefore, G6P enters glycolysis to provide ATP for contraction. * **Von Gierke Disease (GSD Type I):** Caused by a deficiency of Glucose-6-phosphatase, leading to severe fasting hypoglycemia and hepatomegaly.

Q: A 2-month-old infant presents with generalized muscle weakness and a "floppy infant" appearance. Additional features include macroglossia, feeding difficulty, hepatomegaly, and hypertrophic cardiomyopathy. What is the diagnosis?

Type II Glycogen Storage Disease (GSD). **Explanation:** The clinical presentation of a "floppy infant" (hypotonia) combined with **macroglossia** and **hypertrophic cardiomyopathy** is classic for **Type II Glycogen Storage Disease (Pompe Disease)**. Unlike other GSDs, Pompe disease is a **lysosomal storage disorder** caused by a deficiency of **Acid Alpha-Glucosidase (Acid Maltase)**. This enzyme is responsible for breaking down glycogen within lysosomes. Its deficiency leads to massive accumulation of glycogen in cardiac, skeletal, and smooth muscle cells. The involvement of the heart (cardiomegaly/cardiomyopathy) is the pathognomonic feature that distinguishes it from other GSDs in infancy. **Analysis of Incorrect Options:** * **Type I (von Gierke):** Characterized by severe fasting hypoglycemia, lactic acidosis, and hyperuricemia. It involves the liver and kidneys, but **not the muscles or heart**. * **Type III (Cori):** Similar to Type I but milder, with normal lactate levels. While it can involve muscles, it does not typically present with the severe infantile cardiomyopathy seen in Pompe. * **Type IV (Andersen):** Presents primarily with **liver cirrhosis** and failure in early childhood due to the accumulation of abnormal glycogen (amylopectin). **NEET-PG High-Yield Pearls:** * **Pompe Disease** is the only GSD that is also a **Lysosomal Storage Disease**. * **ECG Finding:** Characteristically shows **giant QRS complexes** and a short PR interval. * **Biopsy:** Shows PAS-positive material within lysosomes. * **Treatment:** Enzyme Replacement Therapy (Alglucosidase alfa).

Q: Which metabolic process is responsible for the conversion of fat to glucose?

Gluconeogenesis. **Explanation:** **1. Why Gluconeogenesis is Correct:** Gluconeogenesis is the metabolic pathway that results in the generation of glucose from non-carbohydrate precursors. In the context of "fat to glucose," it is important to note that while humans cannot convert even-chain fatty acids into glucose, the **glycerol backbone** of triglycerides is a major substrate for gluconeogenesis. Glycerol is phosphorylated to glycerol-3-phosphate and then converted to dihydroxyacetone phosphate (DHAP), which enters the gluconeogenic pathway to form glucose. Additionally, odd-chain fatty acids yield propionyl-CoA, which enters the Kreb’s cycle as succinyl-CoA and can eventually be converted to glucose. **2. Why Other Options are Incorrect:** * **Glycolysis:** This is the catabolic process of breaking down glucose into pyruvate to produce ATP. It is the functional opposite of gluconeogenesis. * **Kreb’s Cycle (TCA Cycle):** While this cycle is a common oxidative pathway for carbohydrates, fats, and proteins, it primarily serves to generate reducing equivalents (NADH, FADH2) for ATP production. It does not directly synthesize glucose. * **Saponification:** This is a chemical process (hydrolysis of triglycerides with an alkali) used in soap making; it is not a metabolic pathway in the human body. **3. NEET-PG High-Yield Pearls:** * **Key Substrates:** The four primary substrates for gluconeogenesis are **Lactate** (Cori Cycle), **Glycerol** (from fat), **Glucogenic Amino Acids** (mainly Alanine), and **Propionyl-CoA** (from odd-chain fatty acids). * **Rate-Limiting Enzyme:** Fructose-1,6-bisphosphatase. * **Location:** Occurs primarily in the **Liver** (90%) and Kidney (10%). * **The "Fat" Rule:** Acetyl-CoA (from even-chain fatty acids) **cannot** be converted to glucose because the Pyruvate Dehydrogenase reaction is irreversible. Only the glycerol portion of fat is gluconeogenic in humans.

Q: During the conversion of glycerol to pyruvic acid, what is the first glycolytic intermediate to form?

Dihydroxyacetone phosphate. ### Explanation The conversion of glycerol into the glycolytic pathway occurs primarily in the liver. This process involves two key enzymatic steps: 1. **Glycerol Kinase:** Glycerol is first phosphorylated to **Glycerol-3-phosphate** (using ATP). 2. **Glycerol-3-phosphate Dehydrogenase:** Glycerol-3-phosphate is then oxidized to **Dihydroxyacetone phosphate (DHAP)**, reducing $NAD^+$ to $NADH$. **DHAP** is the first true glycolytic intermediate formed. It can then be converted into Glyceraldehyde-3-phosphate by *Triose phosphate isomerase* to proceed through the remainder of glycolysis to form pyruvic acid. #### Analysis of Options: * **D (Correct):** DHAP is the entry point into glycolysis for glycerol. * **C (Incorrect):** 3-phosphoglyceraldehyde (Glyceraldehyde-3-phosphate) is formed *after* DHAP via isomerization; it is not the first intermediate. * **A & B (Incorrect):** 2-phosphoglyceric acid and 3-phosphoglyceric acid are downstream intermediates in the payoff phase of glycolysis, occurring much later in the sequence toward pyruvate. #### NEET-PG High-Yield Pearls: * **Tissue Specificity:** Glycerol kinase is present in the **liver and kidneys** but is **absent in adipose tissue**. Therefore, adipocytes cannot reuse glycerol released from lipolysis; it must be transported to the liver. * **Gluconeogenesis:** This pathway also serves as the mechanism by which glycerol acts as a substrate for gluconeogenesis during fasting. * **Shuttle System:** The conversion of Glycerol-3-P to DHAP is also a component of the **Glycerol-3-phosphate shuttle**, which transports reducing equivalents from the cytosol to the mitochondria for the Electron Transport Chain.

Q: The hallmarks of type Ia glycogen storage disease are all of the following except?

Metabolic alkalosis. **Explanation:** **Type Ia Glycogen Storage Disease (Von Gierke Disease)** is caused by a deficiency of **Glucose-6-Phosphatase**, the enzyme responsible for converting Glucose-6-Phosphate into free glucose. This enzyme is crucial for both glycogenolysis and gluconeogenesis. **Why Metabolic Alkalosis is the correct answer:** In Von Gierke disease, the inability to produce glucose leads to the shunting of Glucose-6-Phosphate into the glycolytic pathway, resulting in excessive production of pyruvate and subsequently **lactic acid**. This leads to **Metabolic Acidosis** (specifically a high anion gap metabolic acidosis), not metabolic alkalosis. **Why the other options are incorrect (Hallmarks of GSD Ia):** * **Hypoglycemia (A):** Severe fasting hypoglycemia occurs because the liver cannot release free glucose into the blood from glycogen stores or via gluconeogenesis. * **Hyperuricemia (C):** Increased G-6-P levels divert into the Pentose Phosphate Pathway, increasing ribose-5-phosphate and purine synthesis. Additionally, lactic acid competes with uric acid for excretion in the kidneys, leading to gouty arthritis. * **Hyperlipidemia (D):** Low insulin and high glucagon levels trigger lipolysis. The liver also increases VLDL synthesis from excess acetyl-CoA, leading to hypertriglyceridemia and "doll-like" facies. **Clinical Pearls for NEET-PG:** * **Key Enzyme:** Glucose-6-Phosphatase (Type Ia); G-6-P Translocase (Type Ib). * **Type Ib specific:** Presents with the same features plus **neutropenia** and recurrent infections. * **Diagnostic Clue:** Hepatomegaly (due to glycogen and fat accumulation) with **no** splenomegaly. * **Treatment:** Frequent oral cornstarch (slow-release glucose) and avoidance of fructose/galactose.

Question 1

A patient presents with muscle cramps on exercise and positive myoglobinemia. What is the most likely disorder?

Accepted Answer

McArdle's disease

Answer

Pompe's disease

Answer

Myotonia congenita

Answer

Myotonic dystrophy

Question 2

Conversion of lactate to glucose requires all except?

Accepted Answer

Phosphofructokinase

Answer

Pyruvate carboxylase

Answer

PEP carboxykinase

Answer

Glucose-6-phosphatase

Question 3

A newborn baby presents with a history of seizures and hepatomegaly. The following feature was noted on ophthalmic examination. What is the most probable diagnosis?

Accepted Answer

Deficiency of Galactose 1-phosphate Uridyltransferase

Answer

Deficiency of Galactokinase

Answer

Deficiency of Ceruloplasmin

Answer

Maternal exposure to X-rays in the antenatal period

Question 4

Which of the following types of reaction does NOT occur in glycolysis?

Accepted Answer

Hydration

Answer

Isomerization

Answer

Phosphoryl transfer

Answer

Aldol cleavage

Question 5

For which glycogen storage disease, enzyme replacement therapy is available?

Accepted Answer

Glycogen storage disease type II

Answer

Glycogen storage disease type I

Answer

Glycogen storage disease type III

Answer

Glycogen storage disease type IV

Question 6

What is the first product of glycogenolysis?

Accepted Answer

Glucose-1-phosphate

Answer

Glucose-6-phosphate

Answer

Glucose-1,6-diphosphate

Answer

Fructose-1-phosphate

Question 7

A 2-month-old infant presents with generalized muscle weakness and a "floppy infant" appearance. Additional features include macroglossia, feeding difficulty, hepatomegaly, and hypertrophic cardiomyopathy. What is the diagnosis?

Accepted Answer

Type II Glycogen Storage Disease (GSD)

Answer

Type I Glycogen Storage Disease (GSD)

Answer

Type III Glycogen Storage Disease (GSD)

Answer

Type IV Glycogen Storage Disease (GSD)

Question 8

Which metabolic process is responsible for the conversion of fat to glucose?

Accepted Answer

Gluconeogenesis

Answer

Glycolysis

Answer

Kreb's cycle

Answer

Saponification

Question 9

During the conversion of glycerol to pyruvic acid, what is the first glycolytic intermediate to form?

Accepted Answer

Dihydroxyacetone phosphate

Answer

2-phosphoglyceric acid

Answer

3-phosphoglyceric acid

Answer

3-phosphoglyceraldehyde

Question 10

The hallmarks of type Ia glycogen storage disease are all of the following except?

Accepted Answer

Metabolic alkalosis

Answer

Hypoglycemia

Answer

Hyperuricemia

Answer

Hyperlipidemia

Carbohydrate Metabolism — MCQs

Carbohydrate Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?